Part-Time
Polysomnographic Technologist
Days, Central Staffing
Memorial Hermann
10,001+ employees
Integrated health system delivering patient-centered care
No salary listed
Texas, USA
In Person
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Memorial Hermann
See people who can refer or advise you
- A high school diploma is required.
- Certification in Basic Life Support is required.
- Registration by the Board of Polysomnographic Technologists as a Registered Polysomnographic Technologist is required.
- At least two years of experience as a Registered Polysomnographic Technologist performing sleep studies is required.
- The position requires occasional or frequent lifting of up to 75–100 pounds and carrying of up to 30 pounds.
- Analyze recorded data according to current American Academy of Sleep Medicine standards.
- Score sleep/wake stages using professionally accepted guidelines.
- Score respiratory events, cardiac events, limb movements, arousals, and other clinical events according to center-specific protocols.
- Generate accurate reports by tabulating clinical event data and discuss results and treatment outcomes with laboratory physicians.
- Provide quality-assurance feedback for every study and staff education for areas of concern when necessary.
- Successfully complete monthly inter-scorer reliability examinations according to system standards.
- Deliver appropriate and safe patient care at a competent level according to the age or population of the patient.
- Prepare for and conduct overnight testing procedures.
- Review patient records, examine orders and protocols for studies, and recognize the chief sleep/wake complaint.
- Interview patients to assess current medications, recent alcohol or caffeine ingestion, current sleep patterns, and the need for treatment intervention during the study.
- Perform complex procedures and special activities and evaluate/test all patient populations being served.
- Adhere to established safety, sanitation, and equipment-maintenance procedures.
- Ensure safe care for patients, staff, and visitors and comply with organizational policies, procedures, and standards involving time management, supply management, productivity, and service quality.
- Meet mandatory and continuing-education and skills-competency requirements.
- Support department-based goals that contribute to organizational success.
- Serve as a preceptor, mentor, and resource to less experienced staff.
- Provide compassionate, personalized, safe, and efficient experiences to patients and colleagues.
Memorial Hermann Health System is a nonprofit, community-owned health system serving the Greater Houston area with more than 260 care delivery sites. It delivers safe, high-quality, patient-centered care through an integrated network that combines clinical expertise with advanced technology. The system differentiates itself through its community ownership, value-driven culture, and broad network of hospitals, clinics, and specialty services. Its goal is to improve regional health outcomes by providing comprehensive, accessible care and leveraging innovation to personalize treatment.
Company Size
10,001+
Company Stage
Grant
Total Funding
$5M
Headquarters
Houston, Texas
Founded
1907
Get referred to Memorial Hermann
See people who can refer or advise you
Simplify's Take
What believers are saying
- June 16, 2026 Helix Genomic Advantage gives employees clinical genomic screening and targeted care.
- June 2026 Texas funded Memorial Hermann $750,000 to add a second mobile stroke unit.
- HEAL High School reopened August 2026 with simulated hospital training and paid apprenticeships.
What critics are saying
- Memorial Hermann will terminate commercial health plans by end-2027 after solvency concerns.
- Federal prosecutors indicted transplant director John Bynon in February 2026; families still sue.
- The September 2025 hidden-camera class action threatens reputation and trial expenses in 2026.
What makes Memorial Hermann unique
- Memorial Hermann pioneered America’s first mobile stroke unit in 2014, now expanding it in 2026.
- TIRR Memorial Hermann ranked No. 1 Texas rehabilitation hospital in 2026-2027 U.S. News.
- GenoME and Helix Genomic Advantage embed population genomics into workforce care and research.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Wellness Program
Mental Health Support
Growth & Insights and Company News
6 month growth
↑ 14%1 year growth
↑ 14%2 year growth
↑ 14%Former Houston transplant surgeon's federal case moves toward trial. By Megan Reyna - KHOU 11 Aug 19, 2026 Preview this article 1 min Dr. John Stevenson Bynon, 66, the former surgical director of liver transplantation at Memorial Hermann, is accused of falsifying medical records. Don't Stop Here - Continue Reading For $1 Per Week Secure 4 weeks of award-winning news and trusted insights Subscribe for only $4
Helix secures AstraZeneca partnership to power drug discovery with US genomic data. July 8, 2026 AstraZeneca has signed a multi-year agreement with San Mateo-based Helix to access its GenoSphere clinico-genomic cohort platform for drug discovery and development, adding a major US commercial data source to its existing population genomics infrastructure. The deal gives AstraZeneca (Nasdaq: AZN) access to Helix's continuously growing, deeply phenotyped cohorts spanning cardiometabolic, respiratory, and autoimmune disease areas. The agreement is AstraZeneca's latest move in a systematic multi-source genomics strategy and arrives as Helix establishes itself as a recurring platform partner to top-tier pharma. Financial terms were not disclosed. GenoSphere cohorts combine Exome+ genomic sequencing with longitudinal electronic health record data averaging 13 years of follow-up per patient, drawn from the Helix Research Network - described by the company as the largest precision health network in North America. The datasets are de-identified and fully consented, with the option to launch targeted follow-on studies. The platform is designed to support target identification, disease biology research, and patient stratification across the drug development lifecycle, functioning as a discovery infrastructure layer rather than a single-indication tool. Helix recently launched its Genomic Advantage program with Nebraska Medicine and Memorial Hermann Health System, adding new health system partners that feed the underlying research network. For AstraZeneca, the Helix deal adds a commercially managed, US-based, exome-sequenced cohort to a genomics portfolio that already includes co-funded access to the UK Biobank whole-genome sequencing dataset and membership in the Alliance for Genomic Discovery - a consortium that includes AbbVie, Amgen, GSK, Merck, and Novo Nordisk, among others. AstraZeneca's Centre for Genomics Research has publicly stated a goal of analyzing 2 million genomes by 2026. The Helix agreement adds a North American commercial data layer to AstraZeneca's existing European biobank partnerships. Helix previously signed a multi-year collaboration with GSK, announced in January 2026 using an identical structural template, with AstraZeneca now the third major pharma to sign onto the same GenoSphere platform following Helix's March 2026 agreement with Alnylam Pharmaceuticals. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Cadence, the clinical AI company managing chronic care for older adults, announced a $100 million Series C, amid adoption of its AI-powered care model across...
Nebraska Medicine and Memorial Hermann Health System have launched Helix Genomic Advantage, integrating clinical-grade genomic insights into care delivery for their workforces. The programme follows a similar launch with St. Luke's University Health Network. Both health systems are Helix Research Network partners operating large-scale community genomics studies. The Genomic Advantage model aims to implement precision medicine for targeted populations whilst reducing costs, addressing the high expense that has historically prevented scaling diagnostic genomics. "The high cost of diagnostic genomics has served as a significant barrier, preventing health systems from scaling these insights for patient populations," said James Lu, Helix CEO and co-founder. The programme aligns incentives to drive expanded access and total cost of care reduction across risk-based populations.
Memorial Hermann Is Leaving the Houston Market. Here's What Every Business Owner and HR Manager Needs to Know